Merck: Bullish Setup Into Q1 Earnings
Source: SeekingAlpha
2026-04-27 08:39:40 ET
So, I am here again, with my analysis of Merck & Co., Inc. ( MRK ).
In my previous article , " Merck: Why Investors Should Remain Bullish Despite Patent Risks, " I discussed why the subcutaneous version of pembrolizumab , called Keytruda Qlex, has a high chance of becoming Merck's next blockbuster, as well as the follow-up data from the Phase 2b KEYNOTE-942 trial, evaluating Moderna's ( MRNA ) intismeran autogene+Keytruda....
Read the full article on Seeking Alpha
For further details see:
Merck: Bullish Setup Into Q1 Earnings
Novartis AG
NASDAQ: NVS
NVS Trading
-0.26% G/L:
$150.47 Last:
852,043 Volume:
$151.84 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
